Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

NCT00679263 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: MN-221
DRUG: MN-221
DRUG: Placebo

Sponsor

MediciNova